Welcome to our dedicated page for Insulet Corporation news (Ticker: $PODD), a resource for investors and traders seeking the latest updates and insights on Insulet Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Insulet Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Insulet Corporation's position in the market.
Rhea-AI Summary
Insulet Corporation (PODD) to present at Nasdaq 29th Investor Conference in London and J.P. Morgan Annual Healthcare Conference in San Francisco. Live audio webcasts and replays available on investors.insulet.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
News
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) announced its financial results for the third quarter of 2023. The company reported revenue of $432.7 million, up 27.0% compared to the prior year. Gross margin increased to 67.8%, and operating income increased to $54.8 million. Net income was $51.9 million, compared to a net loss of $5.2 million in the prior year. The company raised its full-year revenue guidance to a range of 26% to 27%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.76%
Tags
-
Rhea-AI Summary
Insulet Corporation announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day. The company will ring the closing bell at Nasdaq Stock Market on November 14 and will host educational events. Insulet is committed to raising awareness and providing support for people with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
Rhea-AI Summary
Sensata Technologies announced that Brian K. Roberts has been named as the new CFO, succeeding Paul Vasington who will retire. Brian will assume leadership of all global financial activities. Brian brings decades of finance and leadership experience, including as CFO at Insulet Corporation and Digitas, Inc. Sensata will conduct a conference call to discuss its Q3 2023 financial results and outlook for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
Insulet Corporation has received FDA clearance for the Omnipod 5 App for iPhone, making it the first company to offer a tubeless automated insulin delivery system with full control from a compatible Android and iOS smartphone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
-
Rhea-AI Summary
Insulet Corporation reaffirms guidance for Q3 and FY 2023, announces CFO resignation and interim replacement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
Rhea-AI Summary
Insulet Corporation announces schedule of events and presentations at EASD 2023, highlighting extended real-world evidence of improved outcomes using Omnipod 5 Automated Insulin Delivery System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
-
Rhea-AI Summary
Insulet Corporation plans to release its financial results for Q3 2023 on November 2, 2023. A conference call will be hosted at 4:30 p.m. (Eastern Time).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
News
Rhea-AI Summary
Insulet Corporation launches Omnipod 5 Automated Insulin Delivery System in Germany, expanding its market presence. The system has shown improved clinical outcomes in the U.S., making it an attractive option for individuals with type 1 diabetes. Omnipod 5 is the first CE marked tubeless automated insulin delivery system that integrates with Dexcom G6 Continuous Glucose Monitoring System. The company aims to make Omnipod 5 available for the majority of its European customers by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) to present at three upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Insulet Corporation
Nasdaq:PODD
PODD Rankings
PODD Stock Data
12.14B
69.53M
0.31%
103.67%
4.46%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
ACTON
About PODD
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down